• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Financial Officer Mahboob Vaseem was granted 22,059 shares, increasing direct ownership by 149% to 36,897 units (SEC Form 4)

    7/21/25 5:14:36 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care
    Get the next $KMTS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Mahboob Vaseem

    (Last) (First) (Middle)
    C/O KESTRA MEDICAL TECHNOLOGIES, LTD.
    3933 LAKE WASHINGTON BLVD NE, SUITE 200

    (Street)
    KIRKLAND WA 98033

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    07/17/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Shares 07/17/2025 A 22,059(1) A $0.00 36,897 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Options (2) (2) 03/06/2035 Common Shares 159,000 159,000 D
    Explanation of Responses:
    1. Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest 7,353 on July 17, 2026, 7,353 on July 17, 2027 and 7,354 on July 17, 2028.
    2. Includes 79,500 options that will vest on March 6, 2026, and the remaining 79,500 will vest monthly over the following year.
    Remarks:
    Exhibit 24.1 - Power of Attorney
    /s/ Vaseem Mahboob 07/21/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KMTS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $KMTS

    DatePrice TargetRatingAnalyst
    3/31/2025$30.00Buy
    BofA Securities
    3/31/2025$29.00Outperform
    Wolfe Research
    3/31/2025$24.00Neutral
    Goldman
    3/31/2025$28.00Buy
    Stifel
    3/31/2025$28.00Overweight
    Wells Fargo
    3/31/2025$27.00Overweight
    Piper Sandler
    More analyst ratings

    $KMTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Webster Brian Daniel was granted 88,235 shares, increasing direct ownership by 29% to 397,577 units (SEC Form 4)

      4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

      7/21/25 5:20:31 PM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Mahboob Vaseem was granted 22,059 shares, increasing direct ownership by 149% to 36,897 units (SEC Form 4)

      4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

      7/21/25 5:14:36 PM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Officer Umberger Traci S was granted 29,412 shares, increasing direct ownership by 32% to 120,836 units (SEC Form 4)

      4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

      7/21/25 5:13:04 PM ET
      $KMTS
      Medical/Dental Instruments
      Health Care

    $KMTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities initiated coverage on Kestra Medical Technologies with a new price target

      BofA Securities initiated coverage of Kestra Medical Technologies with a rating of Buy and set a new price target of $30.00

      3/31/25 8:54:18 AM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Wolfe Research initiated coverage on Kestra Medical Technologies with a new price target

      Wolfe Research initiated coverage of Kestra Medical Technologies with a rating of Outperform and set a new price target of $29.00

      3/31/25 8:13:51 AM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on Kestra Medical Technologies with a new price target

      Goldman initiated coverage of Kestra Medical Technologies with a rating of Neutral and set a new price target of $24.00

      3/31/25 8:13:51 AM ET
      $KMTS
      Medical/Dental Instruments
      Health Care

    $KMTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

      Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing

      7/21/25 7:00:00 AM ET
      $BBNX
      $BCAX
      $KMTS
      $MORF
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Kestra Medical Technologies Wins 2025 Top Workplaces Industry Award, A National Recognition

      KIRKLAND, Wash., July 17, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, announced today that it is a 2025 Top Workplaces Industry winner by Energage, a purpose-driven organization that develops solutions to build and brand Top Workplaces. The Top Workplaces program has a 17-year history of surveying and celebrating people-first organizations nationally and across 60 regional markets. Top Workplaces Industry awards celebrate organizations that have built people-first workplace cultures within their sector. The award marks them as an employer of choice for those seeking employment in the industry. "Being

      7/17/25 8:00:00 AM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2025 Financial Results

      KIRKLAND, Wash., July 15, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today reported financial results for the fourth quarter and fiscal year ended April 30, 2025. Financial Highlights Reported revenue of $17.2 million in Q4 FY25, an increase of 71% compared to the prior year period.Reported revenue of $59.8 million in FY25, an increase of 115% compared to FY24.Generated gross margin of 44.3% in Q4 FY25 compared to 13.9% in the prior year period.Generated gross margin of 40.5% in FY25 compared to 1.3% in FY24.Initiated FY26 revenue guidance of $85 million, an increase of 42% compared to FY25. "We cap

      7/15/25 4:01:00 PM ET
      $KMTS
      Medical/Dental Instruments
      Health Care

    $KMTS
    SEC Filings

    See more
    • SEC Form 10-K filed by Kestra Medical Technologies Ltd.

      10-K - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

      7/17/25 4:06:25 PM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Kestra Medical Technologies Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

      7/15/25 4:12:01 PM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Kestra Medical Technologies Ltd.

      8-K - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

      6/6/25 6:08:27 AM ET
      $KMTS
      Medical/Dental Instruments
      Health Care

    $KMTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

      BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

      6/23/25 9:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Kestra Medical Technologies Announces Appointment of Conor Hanley to its Board of Directors

      KIRKLAND, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Conor Hanley as an independent director to its board, effective June 4, 2025. "I am delighted to welcome Conor to our board of directors," said Brian Webster, President and CEO of Kestra Medical Technologies. "He brings deep expertise in medical technology and cardiac care and will serve as an invaluable strategic resource as we grow and expand the reach of the ASSURE® system." Mr. Hanley is a chartered director and currently serves as CEO of FIRE1, a venture-backed connected medical device sol

      6/5/25 8:00:00 AM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

      Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son

      4/3/25 11:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care

    $KMTS
    Financials

    Live finance-specific insights

    See more
    • Kestra Medical Technologies Wins 2025 Top Workplaces Industry Award, A National Recognition

      KIRKLAND, Wash., July 17, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, announced today that it is a 2025 Top Workplaces Industry winner by Energage, a purpose-driven organization that develops solutions to build and brand Top Workplaces. The Top Workplaces program has a 17-year history of surveying and celebrating people-first organizations nationally and across 60 regional markets. Top Workplaces Industry awards celebrate organizations that have built people-first workplace cultures within their sector. The award marks them as an employer of choice for those seeking employment in the industry. "Being

      7/17/25 8:00:00 AM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Kestra Medical Technologies, Ltd. to Report Fourth Quarter and Fiscal Year 2025 Results on July 15

      KIRKLAND, Wash., July 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced that it will report fourth quarter and fiscal year 2025 financial results on Tuesday, July 15. Management will host a corresponding conference call at 4:30 p.m. Eastern Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digit

      7/1/25 8:00:00 AM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Kestra Medical Technologies, Ltd. to Report Third Quarter Fiscal 2025 Financial Results on April 14

      KIRKLAND, Wash., April 02, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced that it will report financial results for the third quarter fiscal 2025 on Monday, April 14. Management will host a corresponding conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable

      4/2/25 4:05:00 PM ET
      $KMTS
      Medical/Dental Instruments
      Health Care